AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality ...

Complete Response Letters recently issued by the FDA signal heightened scrutiny of trial design and reinforce the agency’s shifting regulatory expectations for sponsors and CROs.

New statistical frameworks such as net treatment benefit offer a multidimensional approach to evaluating efficacy, safety, ...

Integration of trial sequential analysis to control random errors in meta-analysis findings. Restriction to randomised controlled trials may limit applicability ... with evidence-based support and to ...

Background The evidence on associations between ultra-processed foods (UPF) and lung cancer risk is limited and inconsistent.

Media Release The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build momentum and is recruiting patients at a growing number of activated clinical ...